"Rituximab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.
| Descriptor ID |
D000069283
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.075.785 D12.776.124.790.651.114.224.075.785 D12.776.377.715.548.114.224.284.785
|
| Concept/Terms |
Rituximab- Rituximab
- CD20 Antibody, Rituximab
- Rituximab CD20 Antibody
|
Below are MeSH descriptors whose meaning is more general than "Rituximab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.486.485.114.224.075]
- Rituximab [D12.776.124.486.485.114.224.075.785]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.790.651.114.224.075]
- Rituximab [D12.776.124.790.651.114.224.075.785]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.377.715.548.114.224.284]
- Rituximab [D12.776.377.715.548.114.224.284.785]
Below are MeSH descriptors whose meaning is more specific than "Rituximab".
This graph shows the total number of publications written about "Rituximab" by people in this website by year, and whether "Rituximab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 4 | 4 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 5 | 5 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 4 | 4 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 3 | 4 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 0 | 3 | 3 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Rituximab" by people in Profiles.
-
Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia. J Geriatr Oncol. 2023 Jul; 14(6):101538.
-
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet Oncol. 2022 08; 23(8):1021-1030.
-
Takotsubo Cardiomyopathy Secondary to Rituximab. Am J Ther. 2022 07 01; 29(4):451-454.
-
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022 06 18; 399(10343):2294-2308.
-
Outcomes of cardiac diffuse large B-cell lymphoma (DLBCL) in the rituximab era. Int J Cardiol. 2021 Sep 15; 339:146-149.
-
Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Clin Lymphoma Myeloma Leuk. 2021 03; 21(3):139-146.
-
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020 10; 18(10):2496-2502.
-
Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020 10; 18(10):2503-2512.
-
Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab. Am J Hematol. 2020 04; 95(4):E76-E77.
-
Treatment of Immune Thrombocytopenia in Adults: Version 2019. Mayo Clin Proc. 2019 11; 94(11):2161-2163.